Author: admin

Follow Our DDT Qualification Journey

Welcome to Specificity Insights, our blog about current developments in antibody specificity testing! Over the coming months, we’ll be releasing a multi-part series about […]

Webinar Presented by Integral Molecular and IPWatchdog – Resurrecting Antibody Genus Protection: Allowed Claims Through CDR-Scanning

Thursday, March 5, 2026 12 pm ET View the recording New antibody patenting strategies, such as structure-based genus and means plus function claims, are […]

Integral Molecular’s Membrane Proteome Array™ Nears FDA Qualification as a Drug Development Tool

MPA on track to become the first NAM approved by the FDA for specificity testing Philadelphia – Integral Molecular, a leader in antibody discovery […]

10x Faster Virus Neutralization Testing With Launch of Integral Molecular’s Ready Reporter Virus™ Kit

Automation-compatible, safe assay delivers same-day results to accelerate vaccine and therapeutic antibody development Philadelphia – Integral Molecular, a leader in developing innovative tools for […]

Integral Molecular Out-Licenses First-in-Class Antibody Panel Targeting SLC2A4 Glucose Transporter

Philadelphia –Integral Molecular, the industry leader in discovering antibodies against membrane proteins, is pleased to announce that it has out-licensed a panel of highly […]

Integral Molecular Named a Top Workplace by Philadelphia Inquirer

Philadelphia – Integral Molecular, a founding member of Philadelphia’s biotechnology hub, has been recognized as a 2025 Top Workplace by the Philadelphia Inquirer. This […]

Webinar Presented by Integral Molecular and Fierce Biotech – Best Practices for Antibody Specificity Testing for IND Submissions

Thursday, June 5, 2025 View the recording Off-target binding can be a significant hurdle in the development of antibody-based therapies, contributing to both drug […]

Integral Molecular Launches Paratope-PLUS™, a CDR-Scanning Service to Support Robust Patent Claims and Antibody Engineering

Technology aligns with new USPTO guidance for writing antibody patent claims and enables antibody engineering for novel intellectual property Philadelphia – Integral Molecular, a […]

Integral Molecular’s Out-licensed Bispecific Antibody Enters Clinical Trial for Treating Solid Tumors

Philadelphia –Integral Molecular, a leader in antibody discovery against membrane proteins, is pleased to announce that its out-licensed anti-Claudin 6 (CLDN6) bispecific antibody, CTIM-76, […]